Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung.
Adenocarcinoma
/ drug therapy
Afatinib
/ administration & dosage
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Ascites
/ drug therapy
Bevacizumab
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Deoxycytidine
/ administration & dosage
Erlotinib Hydrochloride
/ administration & dosage
Female
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Peritoneal Neoplasms
/ drug therapy
Prognosis
Gemcitabine
bevacizumab
lung adenocarcinoma
malignant ascites
Journal
Asia-Pacific journal of clinical oncology
ISSN: 1743-7563
Titre abrégé: Asia Pac J Clin Oncol
Pays: Australia
ID NLM: 101241430
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
26
06
2018
accepted:
30
12
2018
pubmed:
30
1
2019
medline:
4
12
2019
entrez:
30
1
2019
Statut:
ppublish
Résumé
Lung cancer with malignant peritoneal carcinomatosis and malignant ascites is rare, often indicates the terminal stage, and is refractory to treatment. The median survival time of lung cancer patients with malignant ascites has been reported to be as short as 15 days to 2 months in retrospective studies. We reviewed all lung cancer patients who had cytologically or pathologically proven malignant ascites and received aggressive therapy including chemotherapy, anti-angiogenesis agents and target therapy at a Taiwan hospital from January 2015 to December 2017. In addition, we searched PubMed using the terms "lung cancer," "peritoneal carcinomatosis" and "malignant ascites" to find other studies reporting experience of such treatment. Three consecutive lung cancer patients with malignant ascites (3/265, 1.13%) were included in this case series study, all of whom received bevacizumab with three other drugs (erlotinib, afatinib and gemcitabine). All of the patients showed a good response to treatment with a marked decrease in ascites. Two of the patients had a long progression-free survival time of more than 5 months. In the literature review, several cases reports and case series documented the treatment efficacy, however no prospective or retrospective studies reported treatment strategies. Aggressive treatment for lung cancer with malignant ascites is encouraged when possible. Bevacizumab-based treatment may serve as one effective treatment strategy for non-squamous cell lung carcinoma with malignant ascites. Further prospective trials are urgently needed.
Substances chimiques
Deoxycytidine
0W860991D6
Bevacizumab
2S9ZZM9Q9V
Afatinib
41UD74L59M
Erlotinib Hydrochloride
DA87705X9K
Gemcitabine
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e126-e131Informations de copyright
© 2019 John Wiley & Sons Australia, Ltd.
Références
Satoh H, Ishikawa H, Yamashita YT, Kurishima K, Ohtsuka M, Sekizawa K. Peritoneal carcinomatosis in lung cancer patients. Oncol Rep. 2001;8:1305-1307.
Su HT, Tsai CM, Perng RP. Peritoneal carcinomatosis in lung cancer. Respirology. 2008;13:465-467.
Tanriverdi O, Barutca S, Meydan N. Relapse with isolated peritoneal metastasis in lung adenocarcinoma: case report and review of the literature. Contemp Oncol (Pozn). 2012;16:586-589.
Sereno M, Rodriguez-Esteban I, Gomez-Raposo C, et al. Lung cancer and peritoneal carcinomatosis. Oncol Lett. 2013;6:705-708.
Hanane K, Salma B, Khadija B, et al. Peritoneal carcinomatosis, an unusual and only site of metastasis from lung adenocarcinoma. Pan Afr Med J. 2016;23:60.
Kobayashi H, Wakuda K, Takahashi T. Effectiveness of afatinib in lung cancer with paralytic ileus due to peritoneal carcinomatosis. Respirol Case Rep. 2016;4:e00197.
Kamaleshwaran KK, Joseph J, Kalarikal RK, Shinto AS. Image findings of rare case of peritoneal carcinomatosis from non small cell lung cancer and response to erlotinib in F-18 FDG positron emission tomography/computed tomography. Indian J Nucl Med. 2017;32:140-142.
Yang CJ, Hwang JJ, Kang WY, et al. Gastro-intestinal metastasis of primary lung carcinoma: clinical presentations and outcome. Lung Cancer. 2006;54:319-323.
McNeill PM, Wagman LD, Neifeld JP. Small bowel metastases from primary carcinoma of the lung. Cancer. 1987;59:1486-1489.
Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg. 2004;198:999-1011.
Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42:589-597.
Patil T, Aisner DL, Noonan SA, et al. Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer. 2016;96:27-32.
Zebrowski BK, Yano S, Liu W, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res. 1999;5:3364-3368.
Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol. 1998;153:1249-1256.
Verheul HM, Hoekman K, Jorna AS, Smit EF, Pinedo HM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist. 2000;5(Suppl 1):45-50.
Numnum TM, Rocconi RP, Whitworth J, Barnes MN. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol. 2006;102:425-428.
Aoyagi K, Kouhuji K, Miyagi M, et al. Molecular targeting therapy using bevacizumab for peritoneal metastasis from gastric cancer. World J Crit Care Med. 2013;2:48-55.
Braghiroli MI, Sabbaga J, Hoff PM. Bevacizumab: overview of the literature. Expert Rev Anticancer Ther. 2012;12:567-580.
Zhao H, Li X, Chen D, et al. Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial. Med Oncol. 2015;32:292.
Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15:1236-1244.